Your browser doesn't support javascript.
loading
Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
Im, San Hae; Jang, Mincheol; Park, Ji-Ho; Chung, Hyun Jung.
Afiliação
  • Im SH; Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
  • Jang M; Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
  • Park JH; Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea. jihopark@kaist.ac.kr.
  • Chung HJ; KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), 291, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea. jihopark@kaist.ac.kr.
J Nanobiotechnology ; 22(1): 175, 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38609947
ABSTRACT
Nonviral delivery of the CRISPR/Cas9 system provides great benefits for in vivo gene therapy due to the low risk of side effects. However, in vivo gene editing by delivering the Cas9 ribonucleoprotein (RNP) is challenging due to the poor delivery into target tissues and cells. Here, we introduce an effective delivery method for the CRISPR/Cas9 RNPs by finely tuning the formulation of ionizable lipid nanoparticles. The LNPs delivering CRISPR/Cas9 RNPs (CrLNPs) are demonstrated to induce gene editing with high efficiencies in various cancer cell lines in vitro. Furthermore, we show that CrLNPs can be delivered into tumor tissues with high efficiency, as well as induce significant gene editing in vivo. The current study presents an effective platform for nonviral delivery of the CRISPR/Cas9 system that can be applied as an in vivo gene editing therapeutic for treating various diseases such as cancer and genetic disorders.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Nanopartículas / Sistemas CRISPR-Cas / Edição de Genes / Lipossomos Idioma: En Revista: J Nanobiotechnology Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Nanopartículas / Sistemas CRISPR-Cas / Edição de Genes / Lipossomos Idioma: En Revista: J Nanobiotechnology Ano de publicação: 2024 Tipo de documento: Article